Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study

Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era

(2014) L. Tao et al.   BLOOD

Impact of Neighborhood and Individual Socioeconomic Status on Survival after Breast Cancer Varies by Race/Ethnicity: The Neighborhood and Breast Cancer Study

(2014) S. Shariff-Marco et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society

(2014) Marcello Bertoluci et al.   Diabetology & Metabolic Syndrome

Socioeconomic Disparities in Mortality After Cancer Surgery

(2014) Bradley N. Reames et al.   JAMA Surgery

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials*

(2013) A. J. Templeton et al.   ANNALS OF ONCOLOGY

Overview and Management of Cardiac Adverse Events Associated With Tyrosine Kinase Inhibitors

(2013) D. J. Lenihan et al.   ONCOLOGIST

Cancer Survivorship: Cardiotoxic Therapy in the Adult Cancer Patient; Cardiac Outcomes With Recommendations for Patient Management

(2013) Richard M. Steingart et al.   SEMINARS IN ONCOLOGY

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡

(2012) S. George et al.   ANNALS OF ONCOLOGY

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

(2012) Alexander Levitzki   Annual Review of Pharmacology and Toxicology

Cancer drugs and the heart: importance and management

(2012) T. M. Suter et al.   EUROPEAN HEART JOURNAL

Clinical cardiac safety profile of nilotinib

(2012) T. D. Kim et al.   HAEMATOLOGICA

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

(2012) Heikki Joensuu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs

(2012) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of physician billing and hospitalization data to identify patients with ischemic heart disease using data from the Electronic Medical Record Administrative data Linked Database (EMRALD

(2011) Karen Tu et al.   CANADIAN JOURNAL OF CARDIOLOGY

Clinical Research: Show Us the Data

(2011) Alberto Ocana et al.   JOURNAL OF CLINICAL ONCOLOGY

Toxicity as a Biomarker of Efficacy of Molecular Targeted Therapies: Focus on EGFR and VEGF Inhibiting Anticancer Drugs

(2011) R. Dienstmann et al.   ONCOLOGIST

Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease

(2011) Gerard London et al.   Kidney International Supplements

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

(2010) Thomas Eschenhagen et al.   EUROPEAN JOURNAL OF HEART FAILURE

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

(2010) Michael L. Maitland et al.   JNCI-Journal of the National Cancer Institute

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue

(2009) Ming Hui Chen   Current Cardiology Reports

Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics

(2008) Ming Hui Chen et al.   CIRCULATION

Tyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork?

(2008) Daniel J. Lenihan   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy

(2008) Aarif Y Khakoo et al.   Nature clinical practice. Oncology